Abstract Library

#4573 Digestive neuroendocrine tumours: Patterns, pathways, and progress in personalised management

Introduction: Digestive neuroendocrine tumours (NETs), though rare, are increasingly diagnosed with their incidence rising. Histopathological examination is crucial for diagnosis and grading, based on cell differentiation and proliferation index. Often diagnosed late due to non-specific symptoms, these tumours may present with hormone hypersecretion. Updated classifications now allow better risk stratification and tailored treatments. Advances in imaging, particularly PETscans with somatostatin analogues have improved NET diagnosis and monitoring.

Conference:

Presenting Author: Bensetti Houari A

Authors: Bensetti Houari A, Remouche H, Belkharoubi K,

Keywords: Digestive neuroendocrine tumour, octreoscan, multidisciplinary approach,

#4490 Parietal cell-selective Slc26a9 deletion in mice causes gasdermin D mediates mitochondrial damage and pyroptosis, which is the key event to induce autoimmune gastritis

Introduction: Autoimmune gastritis (AIG) is the basis of gastric malignancy, including neuroendocrine tumour (NET) and gastric cancer (GC). We reported that Slc26a9 is highly expressed in parietal cells (PCs), and its deficiency caused GC.

Conference:

Presenting Author: Liu X

Authors: Ji B, Deng Z, Ma Z, Li T, Tuo B,

Keywords: Slc26a9, autoimmune gastritis, Pyroptosis, gastric mucosal immunity remodelling,

#4456 Characteristics and clinical outcomes after endoscopic or surgical resection of localised sporadic type III gastric NETs: A national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network

Introduction: Type III gastric neuroendocrine tumours (gNETs) are rare indolent tumours with increasing incidence. Endoscopic resection has recently been described to be a safe strategy to remove small, localised type III gNETs.

Conference:

Presenting Author: Perrier M

Authors: Perrier M, Lefort R, Do Cao C, Hautefeuille V, Wallenhorst T,

Keywords: neuroendocrine neoplasm, stomach, endoscopy, surgery, carcinoid,

#4424 Tumour-derived apolipoprotein E induces tip endothelial cell to remodel tumour stroma ratio and promote pancreatic neuroendocrine tumour progression

Introduction: Current clinical trials have shown that single-targeted matrix administration does not improve patient prognosis. The investigation of targeted matrix administration in combination with other therapies is crucial for effectively managing TSR in pNETs.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: APOE, pancreatic neuroendocrine tumour, endothelial cell, tumour stroma ratio, mTOR inhibitor,

#4415 MGMT-activated DUB3 stabilises Nrf2/NCOA4 to modulate apoptosis and ferroptosis, driving temozolomide resistance in pancreatic neuroendocrine tumours

Introduction: O6-methylguanine DNA methyltransferase (MGMT) is a key DNA repair enzyme that removes methyl groups from O(6)-alkylguanine in DNA, introduced by temozolomide (TMZ). Clinical studies in pancreatic neuroendocrine tumours (PanNETs) have confirmed its role in TMZ efficacy.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Chen R, Wang Y, Chen X,

Keywords: pancreatic neuroendocrine tumour, MGMT, temozolomide, ferroptosis,